Procalcitonin Levels in Survivors and Nonsurvivors of Sepsis
Authors:
- Prashant SinghPSPrashant Singh
- Preet Mohinder SinghPSPreet Mohinder Singh
- Anjan TrikhaATAnjan Trikha
- 1 March 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Shock
- Vol. 43 (3) , 212-221
Abstract
Procalcitonin (PCT) is an acute-phase reactant that has been used to diagnose and potentially track the treatment of sepsis. Procalcitonin values rise initially as the infection sets in and eventually fall with resolution. Its level has been reported to be significantly higher in potential nonsurvivors of a septic episode than among survivors. However, there is also a significant amount of evidence against this. We thus conducted a meta-analysis to pool data from all the available studies regarding PCT levels in survivors and nonsurvivors of sepsis. An extensive literature search was conducted using the key words "procalcitonin," "sepsis," and "prognosis." The references of the relevant studies were also scanned. The data from the eligible studies were extracted and analyzed for any significant pooled mean difference between survivors and nonsurvivors both on days 1 and 3. The mean difference in the day 1 PCT values between survivors and nonsurvivors was found to be statistically significant (P = 0.02). The mean difference on day 3 was also statistically significant (P = 0.002). However, in a subgroup consisting of studies on patients with severe sepsis and septic shock, day 1 difference was not found to be significant (P = 0.62). We found heterogeneity of 90% in our study population, which decreased to 62% after exclusion of studies conducted in emergency department patients. Procalcitonin levels in early stages of sepsis are significantly lower among survivors as compared with nonsurvivors of sepsis.Keywords
This publication has 77 references indexed in Scilit:
- Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysisCritical Care, 2013
- Evaluation of the Mortality in Emergency Department Sepsis score combined with procalcitonin in septic patientsThe American Journal of Emergency Medicine, 2013
- Inflammatory parameters and prediction of prognosis in infective endocarditisBMC Infectious Diseases, 2013
- Changes in Circulating Procalcitonin Versus C-Reactive Protein in Predicting Evolution of Infectious Disease in Febrile, Critically Ill PatientsPLOS ONE, 2013
- Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shockBMC Infectious Diseases, 2013
- Diagnostic Value of Dynamics Serum sCD163, sTREM-1, PCT, and CRP in Differentiating Sepsis, Severity Assessment, and Prognostic PredictionMediators of Inflammation, 2013
- Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort studyBMC Infectious Diseases, 2012
- Procalcitonin neutralizes bacterial LPS and reduces LPS-induced cytokine release in human peripheral blood mononuclear cellsBMC Microbiology, 2012
- Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma*Critical Care Medicine, 2009
- Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcomeCritical Care, 2009